Protozoan Vaccine Using Multiple Variable Surface Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for protozoan parasite infections, such as Giardia and Trypanosoma brucei, are inadequate due to antigenic variation, leading to frequent reinfections and drug-resistant strains, with no effective vaccines available.
Innovation Solution
Development of vaccines containing multiple variable surface antigens (VSAs) and microvesicles induced by exposing protozoan parasites to antibodies directed against their VSAs, which stimulate antigenic variation and induce a protective immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs are used to treat protozoan parasite infections, then treatment is provided, but frequent reinfections and drug-resistant strains occur
Solution Approach 1:
The patent applies preliminary action by administering a vaccine before infection occurs, which stimulates the host immune system to produce antibodies against multiple variable surface antigens (VSAs) in advance. This preemptive immunization prevents the parasite from establishing infection or causes rapid clearance upon exposure, thereby avoiding reinfections and the development of drug resistance that occur with conventional treatment approaches.
2Reliability
If conventional treatments are used, then infections are treated, but no effective vaccines are available and reinfection is frequent
Solution Approach 1:
The vaccine provides preliminary protection by pre-stimulating the host immune system to recognize and respond to multiple VSA variants before the parasite can establish infection. This eliminates the need for repeated treatment cycles and reduces the time window for reinfection, as the immune system is already primed to rapidly eliminate the parasite upon exposure.
3Reliability
If the host generates antibodies against all VSAs, then protective immunity is achieved, but this is methodologically impossible
Solution Approach 1:
The vaccine simplifies the complex task of generating immunity against multiple VSAs by pre-stimulating the host immune system in advance. The vaccine formulation, which may contain multiple VSA antigens or genetic material encoding them, triggers the host to produce a broad spectrum of antibodies against different VSA variants before actual infection occurs, thereby achieving protective immunity without requiring complex real-time adaptation during infection.
Solution Approach 2:
The patent applies parameter changes by modifying the antigenic parameters of the parasite through experimental manipulation, such as treating parasites with antibodies or chemical agents to induce antigenic variation. This creates a population of parasites expressing diverse VSAs, which when used as vaccine material, enables the host immune system to recognize and respond to multiple variants simultaneously, thereby achieving broad protective immunity.
4Reliability
If drugs are used to treat infections, then treatment is provided, but resistant strains emerge and continue to cause mortality and morbidity
Solution Approach 1:
The vaccine provides preliminary immunity that prevents infection or rapidly clears the parasite before drug treatment is needed. By establishing protective antibodies in advance against multiple VSA variants, the vaccine eliminates the selective pressure that drives drug resistance development, thereby maintaining treatment efficacy and preventing the emergence of resistant strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccines effectively induce a specific and protective immune response against a wide repertoire of potential surface antigens, providing protection against subsequent infections and potentially limiting the spread of disease.
Implementation Method 1
Some parasites have developed mechanisms of evasion of the immune response (i. e., antigenic variation/serotype replacement), which allows them to survive and complete their life cycle within the host
Implementation Method 2
In the event of subsequent reinfections, the immune system will respond rapidly to these trophozoites thanks to the memory immune response
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
In a first aspect, the present invention relates to vaccines for preventing or treating protozoan parasite infections in an individual whereby the vaccine contains multiple protozoan variable surface antigens (VSAs) of said protozoan parasites microorganism. In particular, protective vaccines are disclosed. In a further aspect, a method for the preparation of the vaccine, in particular, the protective vaccine is described. The vaccine is composed of multiple distinguishable VSAs, preferably comprising the full repertoire of the different VSA encoded by the gene family in said protozoan parasite. In a second aspect, the present invention relates to vaccines for preventing or treating microbial infections in an individual whereby the vaccine contains microvesicles induced by confronting protozoan microorganisms with antibodies directed to their VSAs. In particular, protective vaccines are disclosed. The vaccine is composed of multiple antigens of said protozoan parasite. In a further aspect, methods for the preparation and administration of these vaccines, in particular, the protective vaccines are described.